Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Colorcon
Harvard Business School
McKesson

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOLPIDEM TARTRATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Zolpidem Tartrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00044629 Combined Behavioral/Pharmacological Therapy for Insomnia Completed National Institute of Mental Health (NIMH) Phase 2 2001-09-01 This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
NCT00044629 Combined Behavioral/Pharmacological Therapy for Insomnia Completed Duke University Phase 2 2001-09-01 This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
NCT00283790 Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo Completed Sanofi Phase 4 2006-01-01 Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
NCT00296179 Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro Completed Sanofi Phase 4 2006-02-01 To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.
NCT00296790 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed Sanofi Phase 4 2006-02-01 A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with Escitalopram (Lexapro - antidepressant).
NCT00380081 A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia Completed Transcept Pharmaceuticals Phase 3 2006-04-01 The purpose of this study is to evaluate sleep onset following administration of Transcept zolpidem tartrate sublingual tablet versus placebo in adult insomnia patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zolpidem Tartrate

Condition Name

Condition Name for Zolpidem Tartrate
Intervention Trials
Insomnia 11
Healthy 6
Sleep Initiation and Maintenance Disorders 2
Insomnia Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zolpidem Tartrate
Intervention Trials
Sleep Initiation and Maintenance Disorders 12
Dyssomnias 1
Sleep Wake Disorders 1
Parasomnias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zolpidem Tartrate

Trials by Country

Trials by Country for Zolpidem Tartrate
Location Trials
United States 41
Japan 8
Canada 4
United Kingdom 4
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zolpidem Tartrate
Location Trials
Pennsylvania 4
New Jersey 3
North Carolina 3
New York 3
Georgia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zolpidem Tartrate

Clinical Trial Phase

Clinical Trial Phase for Zolpidem Tartrate
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zolpidem Tartrate
Clinical Trial Phase Trials
Completed 17
Not yet recruiting 3
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zolpidem Tartrate

Sponsor Name

Sponsor Name for Zolpidem Tartrate
Sponsor Trials
Eisai Inc. 4
Transcept Pharmaceuticals 3
Sanofi 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zolpidem Tartrate
Sponsor Trials
Industry 20
Other 4
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.